Skip to content
Back to meeting Original
Nurullah İlhan,MD· @drnurullahilhan · X·· 9 hours agoScore70

SANOVO

Body

SANOVO: 1L EGFR-mutant, MET-overexpressing advanced NSCLC. Savolitinib + osimertinib vs osimertinib: median PFS 24.9 vs 13.8 months (HR 0.56). Primary PFS met. Should MET testing move upfront? @OncoDaily @OncoAlert #ESMO26

3 views · 0 likes · 0 reposts · 0 replies

Source: Nurullah İlhan,MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.